PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-4.77%
Revenue decline while Medical - Pharmaceuticals median is 0.29%. Seth Klarman would investigate if market share loss is temporary.
-4.28%
Cost reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive advantage potential.
-6.75%
Gross profit decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
-2.08%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.81%
Other expenses change of 16.81% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
1.66%
Operating expenses growth near Medical - Pharmaceuticals median of 1.57%. Charlie Munger would verify industry norms.
-3.32%
Total costs reduction while Medical - Pharmaceuticals median is 1.67%. Seth Klarman would investigate advantages.
-4.35%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
15.78%
D&A change of 15.78% versus flat Medical - Pharmaceuticals D&A. Walter Schloss would verify adequacy.
-31.53%
EBITDA decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-28.10%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-35.54%
Operating income decline while Medical - Pharmaceuticals median is 2.16%. Seth Klarman would investigate causes.
-32.31%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
10.94%
Other expenses change of 10.94% versus flat Medical - Pharmaceuticals. Walter Schloss would verify control.
-31.62%
Pre-tax income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-28.20%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-30.25%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-32.23%
Net income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-28.84%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-32.22%
EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-32.22%
Diluted EPS decline while Medical - Pharmaceuticals median is 1.03%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.